Morgan Stanley Upgrades Editas Medicine to Equal-Weight, Announces $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison upgraded Editas Medicine (NASDAQ:EDIT) from Underweight to Equal-Weight and set a price target of $7.

May 09, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Editas Medicine was upgraded by Morgan Stanley from Underweight to Equal-Weight with a new price target of $7.
Upgrades by major financial institutions like Morgan Stanley typically lead to positive short-term price movements as they reflect a change in the institution's view on the stock's valuation and potential. The upgrade from Underweight to Equal-Weight suggests a more favorable outlook on EDIT's performance, potentially leading to increased investor interest and a positive impact on the stock price. The setting of a $7 price target further quantifies the expected valuation, providing a benchmark for investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100